A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
Not yet recruitingOBSERVATIONAL
Enrollment
480
Participants
Timeline
Start Date
July 1, 2025
Primary Completion Date
November 30, 2028
Study Completion Date
November 30, 2028
Conditions
Bacteremia Caused by Gram-Negative BacteriaBacterial Pneumonia
All Listed Sponsors
lead
TTY Biopharm
INDUSTRY
NCT06966284 - A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection | Biotech Hunter | Biotech Hunter